FDA rejects Intercept Pharma’s drug for NASH
Intercept Pharmaceuticals said Monday that the Food and Drug Administration rejected its drug to treat the fatty liver disease known as NASH.
Read The StoryBusiness
Exploring the intersection of finance, pharma, and biotech
A ‘Shark Tank’-funded test for food sensitivity is medically dubious, experts say
Zogenix wins approval for new drug to treat rare type of childhood epilepsy
After a bribery scandal in China, GSK found a suspected whistleblower. The real one is still waiting in the shadows
Watch: Genetic tests promised to help me achieve peak fitness. What I got was a fiasco
All Coverage
advertisement
